21 - 30 out of 36Page size: 10
  1. 2021

  2. Perspective of patients with autoimmune diseases on COVID-19 vaccination

    Boekel, L., Hooijberg, F., van Kempen, Z. L. E., Vogelzang, E. H., Tas, S. W., Killestein, J., Nurmohamed, M. T., Boers, M., Kuijpers, T. W., van Ham, S. M., Eftimov, F., Wieske, L., Rispens, T. & Wolbink, G. J., 1 Apr 2021, In: The Lancet Rheumatology. 3, 4, p. e241-e243

    Research output: Contribution to journal › Comment/Letter to the editor › Academic

  3. Extended dosing of monoclonal antibodies in multiple sclerosis

    van Kempen, Z. L. E., Toorop, A. A., Sellebjerg, F., Giovannoni, G. & Killestein, J., 2021, (E-pub ahead of print) In: Multiple Sclerosis Journal.

    Research output: Contribution to journal › Review article › Academic › peer-review

  4. Natalizumab concentrations during pregnancy in three patients with multiple sclerosis

    Toorop, A. A., Rispens, T., Strijbis, E. M. M., van Oosten, B. W., de Jong, B. A., Uitdehaag, B. M. J., Killestein, J. & van Kempen, Z. L. E., 2021, (E-pub ahead of print) In: Multiple Sclerosis Journal.

    Research output: Contribution to journal › Article › Academic › peer-review

  5. 2020

  6. Infusion-related events during natalizumab: No need for post-infusion monitoring

    Loonstra, F. C., van Rossum, J. A., van Kempen, Z. L. E., Rispens, T., Uitdehaag, B. M. J. & Killestein, J., 1 Oct 2020, In: Multiple sclerosis (Houndmills, Basingstoke, England). 26, 12, p. 1590-1593 4 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  7. COVID-19 in multiple sclerosis: The Dutch experience

    Loonstra, F. C., Hoitsma, E., van Kempen, Z. L. E., Killestein, J. & Mostert, J. P., 1 Sep 2020, In: Multiple sclerosis (Houndmills, Basingstoke, England). 26, 10, p. 1256-1260 5 p.

    Research output: Contribution to journal › Article › Academic › peer-review

  8. Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial

    van Kempen, Z. L. E., Hoogervorst, E. L. J., Wattjes, M. P., Kalkers, N. F., Mostert, J. P., Lissenberg-Witte, B. I., de Vries, A., ten Brinke, A., van Oosten, B. W., Barkhof, F., Teunissen, C. E., Uitdehaag, B. M. J., Rispens, T. & Killestein, J., 11 Aug 2020, In: Neurology. 95, 6, p. e745-e754

    Research output: Contribution to journal › Article › Academic › peer-review

  9. 2019

  10. Pharmacodynamic assessment of cell-bound natalizumab on PBMC samples stored in liquid nitrogen

    ten Brinke, A., Claessen, I., van Kempen, Z. L. E., Killestein, J. & Rispens, T., Oct 2019, In: Journal of immunological methods. 473, 5 p., 112632.

    Research output: Contribution to journal › Article › Academic › peer-review

  11. Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy

    Loonstra, F. C., Verberk, I. M. W., Wijburg, M. T., Wattjes, M. P., Teunissen, C. E., van Oosten, B. W., Uitdehaag, B. M. J., Killestein, J. & van Kempen, Z. L. E., Aug 2019, In: Annals of neurology. 86, 2, p. 322-324

    Research output: Contribution to journal › Comment/Letter to the editor › Academic

  12. Anti-natalizumab antibodies during 8 years of natalizumab treatment: effect on natalizumab concentration and α4-integrin receptor saturation

    van Kempen, Z. L. E., van Rossum, J. A., Doesburg, D., Claessen, I., de Vries, A., ten Brinke, A., van Oosten, B. W., Rispens, T. & Killestein, J., Jul 2019, In: Journal of neurology. 266, 7, p. 1804-1805

    Research output: Contribution to journal › Comment/Letter to the editor › Academic

  13. Abnormalities and erythroblasts in peripheral blood of multiple sclerosis patients treated with natalizumab

    van Rossum, J. A., van Kempen, Z. L. E., Schilder, L., Lissenberg-Witte, B. I., Uitdehaag, B. & Killestein, J., 2019, In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 36, 101382.

    Research output: Contribution to journal › Article › Academic › peer-review

Previous 1 2 3 4 Next

ID: 97640